Trial Profile
Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PET/MRI
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Fluciclovine 18F (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use
- 26 Feb 2020 Status changed from active, no longer recruiting to completed.
- 15 Feb 2020 Results (n=10) assessing potential use of fluciclovine-PET in monitoring response to androgen deprivation therapy (ADT) during initial treatment of patients with newly diagnosed high risk prostate cancer, presented at the 2020 Genitourinary Cancers Symposium.
- 11 Jul 2019 Planned End Date changed from 1 Jun 2019 to 13 Feb 2020.